Daphne D.
- Country
- The Netherlands
- Department
- NA
Research Overview
- Non-Inferiority Study of Reduced Dose Pembrolizumab Versus Standard Dose in Advanced Non-Small Cell Lung Carcinoma for Overall Survival Evaluation
- Phase III Randomized, Double-Blind Study of Toripalimab and Tifcemalimab as Consolidation Therapy in Limited-Stage Small Cell Lung Cancer Post-Chemoradiotherapy
- Phase 3 Randomized Study of PF-08046054/SGN-PDL1V vs. Docetaxel in PD-L1 Positive Non-Small Cell Lung Cancer Patients
Data & Insights
Has run more than one trial at 14 of 169 partner sites.
Specializations
Lung Cancer Research
The investigator specializes in advanced therapeutic approaches for various forms of lung cancer, with particular emphasis on small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
- Limited-stage SCLC treatment optimization
- Advanced NSCLC management
- Post-chemoradiotherapy consolidation strategies
The investigator's work encompasses innovative consolidation therapies following conventional treatments.
Immunotherapy Applications
Focused on advancing immunotherapeutic approaches, particularly investigating immune checkpoint inhibitors and their combinations in lung cancer treatment.
- Novel immunotherapy combinations
- Dose optimization strategies
- Cost-effectiveness in immunotherapy
Their research explores optimal dosing regimens and treatment duration for immunotherapy agents.
Treatment Optimization
The investigator focuses on developing personalized treatment strategies and improving therapeutic outcomes through innovative approaches.
- Consolidation therapy development
- Treatment efficiency assessment
- Therapeutic response monitoring
Their work includes evaluation of treatment efficacy through survival outcomes and progression monitoring.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.